Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | DAO | P14920 | 1/20 | 0.61 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 3/20 | 0.52 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL2835761 | 0.98 | TSHR (0.58) | TSHRDAONAPRTCES1CES2 | |
| Benzoic Acid SCHEMBL28707679 | 0.98 | TSHR (0.58) | TSHRDAONAPRTCES1CES2 | |
| Benzoic Acid SCHEMBL28707677 | 0.98 | TSHR (0.58) | TSHRDAONAPRTCES1CES2 | |
| Benzophenone SCHEMBL5566782 | 0.87 | ALDH1A1 (0.61) | TSHRSRD5A2AKT1HDAC1HDAC2 | |
| Benzamide SCHEMBL11771049 | 0.85 | CYP3A4 (0.67) | TSHRDAONAPRTCES1AKT1 | |
| Benzoic Acid SCHEMBL3266320 | 0.84 | TSHR (0.64) | TSHRDAONAPRTCES1CES2 | |
| Benzoic Acid SCHEMBL31376992 | 0.84 | TSHR (0.78) | TSHRDAONAPRTCES1CES2 | |
| Benzoic Acid SCHEMBL31182419 | 0.83 | ALDH1A1 (0.54) | TSHRDAONAPRTCES1CES2 | |
| Benzoic Acid SCHEMBL9740671 | 0.83 | TSHR (0.61) | TSHRDAONAPRTCES1CES2 | |
| Benzoic Acid SCHEMBL9472196 | 0.83 | TSHR (0.61) | TSHRDAONAPRTCES1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173825-B1 | INK COMPOSITION AND METHOD FOR FORMING THE SAME | HEWLETT PACKARD DEVELOPMENT CO LP (US) | 2016-12-28 | — | — | EP | claimed |
| EP-2173825-A2 | INK COMPOSITION AND METHOD FOR FORMING THE SAME | Hewlett-Packard Development Company, L.P. (US) | 2010-04-14 | — | — | EP | claimed |
| WO-2009058447-A2 | INK COMPOSITION AND METHOD FOR FORMING THE SAME | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2009-05-07 | — | — | WO | claimed |
| US-20090031922-A1 | INK COMPOSITION AND METHOD FOR FORMING THE SAME | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2009-02-05 | — | — | US | claimed |
| US-12247120-B2 | Surface skin, method of producing surface skin, and laminate | ZEON CORPORATION (JP) | 2025-03-11 | — | — | US | disclosed |
| WO-2024203561-A1 | COVER MATERIAL, METHOD FOR PRODUCING COVER MATERIAL, AND LAMINATE | 日本ゼオン株式会社 | 2024-10-03 | — | — | WO | disclosed |
| EP-3121229-B1 | VINYL CHLORIDE RESIN COMPOSITION FOR POWDER MOLDING, VINYL CHLORIDE RESIN MOLDED ARTICLE, AND LAMINATE | ZEON CORP (JP) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024151890-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. | 2024-06-27 | — | — | US | disclosed |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-06-27 | — | — | US | disclosed |
| EP-4366777-A2 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024074813-A1 | A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT | OWLSTONE MEDICAL LIMITED (GB) | 2024-04-11 | — | — | WO | disclosed |
| US-20100272984-A1 | VINYL CHLORIDE RESIN COMPOSITION FOR POWDER MOLDING, MOLDED OBJECT OBTAINED THEREFROM, LAMINATE, VEHICLE INTERIOR MATERIAL, AND METHOD FOR PRODUCING VINYL CHLORIDE RESIN COMPOSITION FOR POWDER MOLDING | ZEON CORPORATION (JP) | 2010-10-28 | — | — | US | disclosed |
| EP-2173825-A2 | INK COMPOSITION AND METHOD FOR FORMING THE SAME | Hewlett-Packard Development Company, L.P. (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009117531-A1 | AURISTATIN DRUG LINKER CONJUGATES | SEATTLE GENETICS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| CN-101454328-A | Novel mch receptor antagonists | LILLY CO ELI (US) | 2009-06-10 | — | — | CN | disclosed |
| WO-2009058447-A2 | INK COMPOSITION AND METHOD FOR FORMING THE SAME | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090031922-A1 | INK COMPOSITION AND METHOD FOR FORMING THE SAME | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. | 2009-02-05 | — | — | US | disclosed |
| US-5994439-A | BLEND CONTAINING TRIMELLITIC ESTER | ZEON KASAI CO., LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| US-5637251-A | POLYHYDRIC ALCOHOL, MONOALLYL AMINE SALT OF 2,5-DIMERCAPTO-1,3,4-THIADIAZOLE, MONOALLYLAMINE SALT OF BENZOIC ACID; CORROSION RESISTANCE | R.T. VANDERBILT COMPANY, INC. (US) | 1997-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207418-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | TSHR 2696/4885DAO 542/4885NAPRT 643/4885 |
| US-20240207429-A1 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PAICS, DHFR, CD44 | TSHR 2696/4885DAO 542/4885NAPRT 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.